OVID

Ovid Therapeutics Inc. (OVID) - Q1 2026 10-Q Summary

Business Context and Reporting Period

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing small molecule medicines for brain disorders, including epilepsy and neuropsychiatric conditions. This report covers the quarterly period ended March 31, 2026. The company operates as a single segment and is classified as a smaller reporting company. As of March 31, 2026, the company had 167,266,466 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Revenue was $0 in Q1 2026 compared to $0.13 million in Q1 2025. The prior period revenue related to royalty agreements with Marinus/Immedica.
• Operating Expenses: Total operating expenses increased by $5.2 million (41%) to $17.8 million.
  • R&D Expenses: Increased by $4.5 million to $11.2 million, driven by preclinical and clinical activity for primary programs OV329 and OV4071.
  • G&A Expenses: Increased by $0.6 million to $6.7 million, primarily due to higher legal and professional fees, offset by lower payroll expenses.
• Other Income: Net other income decreased by $1.5 million to $0.9 million. Q1 2025 included a $1.8 million gain from the recovery of a fraudulent funds transfer, which was not present in Q1 2026.
• Liquidity: Cash and marketable securities increased significantly from $90.4 million at year-end 2025 to $165.6 million at March 31, 2026, due to substantial financing activities.

Guidance, Outlook, and Management Commentary

• Capital Raises: The company executed significant financing in Q1 2026:
  • 2026 Private Placement: Raised net proceeds of $56.2 million via the sale of common stock and pre-funded warrants.
  • Series A Warrant Exercises: Received approximately $50.6 million in net proceeds from the full exercise of Series A warrants (triggered by the initiation of the OV4071 Phase 1 trial in Australia).
  • ATM Program: Sold 1.5 million shares for net proceeds of $2.4 million.
• Cash Runway: Management believes existing cash, cash equivalents, and marketable securities ($165.6 million) are sufficient to fund operations for at least the next 12 months from the filing date.
• Pipeline Updates:
  • OV4071: Received approval to initiate Phase 1 clinical trials in Australia.
  • OV329: Development continues with plans to expand into additional indications (TSC and IS).
  • Soticlestat: No revenue recognized; the program was discontinued by partner Takeda in January 2025 following failed Phase 3 trials.
• Risks: The company faces standard biotech risks including clinical trial uncertainty, regulatory approval challenges, and the need for future capital. Specific risks include potential dilution from future equity offerings and the impact of macroeconomic conditions on financing costs.

Investor Verification Checklist

• Financing Terms: Verify the specific terms and dilution impact of the March 2026 Private Placement and the remaining unexercised Series B Warrants (potential $40 million gross proceeds).
• Cash Burn Rate: Confirm the sustainability of the $13.9 million quarterly operating cash burn against the $165.6 million cash balance to validate the 12-month runway claim.
• OV4071 Trial Status: Monitor the initiation and early data readouts of the Phase 1 trial for OV4071, which triggered the recent warrant exercises.
• License Agreements: Review potential future milestone payment obligations under agreements with AstraZeneca, Northwestern University, and Gensaic, which total up to $279.3 million in contingent payments.
• Internal Controls: Note the remediation of material weaknesses in internal controls identified in late 2024 related to fund transfers; verify ongoing effectiveness in future filings.